Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Shingles affects one in three adults during their lifetime

  80% confidence

• Dynavax strengthens Sanofi's presence in adult vaccination by bringing differentiated vaccines that complement Sanofi's expertise

  80% confidence

• Sanofi's commercial presence, development capabilities and vision of science-based immunization will amplify opportunities for HEPLISAV-B and innovative pipeline to meet important public health needs

  80% confidence

• Joining Sanofi will bring the global scale and expertise needed to maximize the impact of Dynavax's vaccine portfolio

  80% confidence

• The acquisition is expected to close in Q1 2026, subject to satisfaction or waiver of customary closing conditions

  80% confidence

• This transaction and the attractive value it brings serves the best interests of the Company and its shareholders

  80% confidence

• The marketed adult hepatitis B vaccine and shingles vaccine candidate add new options to Sanofi's portfolio and underscore commitment to providing vaccine protection throughout life

  80% confidence

• The Dynavax acquisition agreement should not affect Sanofi's financial outlook for 2025

  80% confidence